Quantitative Flow Ratio on Radial Artery Graft Outcome After Coronary Artery Bypass Grafting
NCT ID: NCT05556590
Last Updated: 2023-07-20
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
135 participants
Study Classification
OBSERVATIONAL
Study Start Date
2022-10-09
Study Completion Date
2023-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In coronary artery bypass grafting (CABG), the use of radial artery (RA) is recommended by the guidelines only to significantly stenosed vessel, due to its high vulnerability to competitive flow. Fractional flow reserve (FFR) is the gold standard to measure physiological significance of coronary lesions and the potential for competitive flow. This study aims to investigate whether the preoperative quantitative flow ratio (QFR) measurement, a novel coronary angiography-based FFR, is associated with RA graft failure post-CABG, and to explore the best cut-off value of QFR for RA grafts using.
Patients from ASRAB-pilot trial (NCT04310995) undergoing primary isolated CABG using RA grafts, and with preoperative coronary angiography (CAG) images available for QFR analysis will be enrolled in this prospective double-blind observational study. QFR analysis will be conducted for all RA-grafted vessels based on preoperative CAG. The primary outcome will RA graft failure (FitzGibbon Grade B,O or S) evaluated by coronary computer tomography angiography or CAG at 7 days and 6 months post-CABG.
Patients from ASRAB-pilot trial (NCT04310995) undergoing primary isolated CABG using RA grafts, and with preoperative coronary angiography (CAG) images available for QFR analysis will be enrolled in this prospective double-blind observational study. QFR analysis will be conducted for all RA-grafted vessels based on preoperative CAG. The primary outcome will RA graft failure (FitzGibbon Grade B,O or S) evaluated by coronary computer tomography angiography or CAG at 7 days and 6 months post-CABG.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quantitative Flow Ratio (QFR) Guided Coronary Artery Bypass Grafting for Patients Undergoing Primary Valve Surgery With Concomitant Coronary Artery Disease
NCT03977129
Primary Valvular Heart Disease With Comorbid Coronary Artery Disease
Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart Disease
ACTIVE_NOT_RECRUITING
NA
Evaluation of Fractional Flow Reserve Calculated by Computed Tomography Coronary Angiography in Patients Undergoing TAVR
NCT03665389
Aortic Valve Stenosis
Coronary Artery Disease
UNKNOWN
NA
Modified Aortic Root Enlargement Procedure
NCT06517537
Small Aortic Annulus
Aortic Root Enlargement Procedure
RECRUITING
Early Outcomes of Concomitant Transcatheter Aortic Valve Implantation and Off-pump Coronary Artery Bypass Grafting in Management of Severe Symptomatic Aortic Stenosis and Coronary Artery Disease
NCT04525339
Aortic Valve Disease
Coronary Artery Disease
UNKNOWN
Comparing Measurements of the Aortic Valve Taken During Surgery With Those Obtained Before Surgery Using Computed Tomography Scans, in Patients Undergoing Surgical Aortic Valve Replacement
NCT07125469
Valvular Heart Disease
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Introduction:
The radial artery (RA) was first used by Carpentier for coronary artery bypass grafting (CABG) in 1971 because of a number of potential advantages, including ease of harvesting, a low propensity for wound infection, a larger diameter than other arterial grafts, and a thick, muscular wall that facilitates the construction of an anastomosis. However, early experience suggested that RA grafts were prone to spasm and functional occlusion, and their use was abandoned for many years. In the past decades, the advent of drug therapy to prevent graft spasm and the adoption of newer harvesting techniques revitalized the interest the use of radial artery. Recently several randomized trials has been conducted to prove the better graft patency over the saphenous vein (SV) and survival benefit was also observed as well. However, due to its unneglectable vulnerability to competitive flow, the recent American and European guidelines for coronary revascularization both limited the use of RA only in significantly stenosed vessels.
Fractional flow reserve (FFR) is the current gold standard to measure the physiological significance of coronary stenosis and the potential for competitive flow. The quantitative flow ratio (QFR) is a novel, intelligent, noninvasive method that enables efficient computation of the FFR from coronary angiography in good concordance with catheter-based FFR. QFR-guided percutaneous coronary intervention (PCI) has been used and showed the improved clinical outcomes in FAVOR III China trial (Comparison of Quantitative Flow Ratio-Guided and Angiography-Guided Percutaneous InterVention in Patients With cORonary Artery Disease).
The Impact of Preoperative Quantitative Flow Ratio on Radial-Artery Graft Outcome after Coronary Artery Bypass Grafting (ASRAB-QUARGO) study aims to investigate whether the preoperative QFR measurement is associated with RA graft patency 6 months after CABG, and to explore the best QFR cut-off value for guiding RA-CABG.
Methods:
Study design- The ASRAB-QUARGO is a single-centre, prospective, double-blind, observational sub-study of the ASRAB-pilot trial (NCT04310995). The study was registered and approved by the ethics committee in out institution. Informed consent was waived under permission from the ethics committee.
Outcome- The primary outcome is the association between preoperative QFR of target vessel and the RA graft outcome at 6 months after CABG. The secondary outcome is the association between preoperative QFR of target vessel and the RA graft outcome at 7 days after CABG.
Study procedures- The complete eligibility criteria for ASRAB-pilot trial is provided in the "eligibility" section. After successfully receiving primary isolated CABG, the patients from the ASRAB-pilot cohort with preoperative CAG images available for QFR analysis were enrolled in this study. QFR analysis was conducted in all vessels grafted based on preoperative CAG images. The images were sent to the core lab (CardHemo, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China) for computation of the QFR. The analysis was performed by the experienced analysts using the AngioPlus system (Pulse Medical Imaging Technology, Shanghai, China) as described \[11-15\]. QFR results were recorded by the core lab and blinded to the patient and surgeon. Apart from the investigational anti-spastic drug from the ASRAB-pilot trial, optimized medical treatment was pursued according to the current American and European guidelines, including smoking cessation counselling and the administration of antiplatelet agents, beta blockers, lipid medications, and angiotensin-converting enzyme inhibitors.
Patients underwent follow-up coronary computer tomography angiography （CCTA）6 months after surgery. Angiographic evaluations were performed by two observers (one radiologist and one cardiac surgeon) blinded to the preoperative QFR values. In the case of ambiguity or disagreement between observers, additional CAG is conducted as possible for further confirmation. For sequential grafts, each segment between two adjacent anastomoses (graft-to-graft anastomosis not included) will be defined as an independent graft and evaluated independently. For composite grafts (eg. T or Y grafts), only RAs directly anastomosed to target vessel were considered as RA grafts. Angiographic patency was graded referring to the FitzGibbon classification: 4 Grade A for widely patent, Grade B for patent with flow limited, Grade S for string sign and Grade O for occluded. Grade B, O and S were considered as diseased. MACE was defined as a composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke and unplanned coronary revascularization.
Sample size- Historical data from our center indicate that graft disease (Grade B, O \& S) occurs in around 20% of grafts 6 months after CABG. We estimated an RA graft disease rate of 10% if QFR ≤ best cut-off value (0.50-0.55 assumed), and 30% if QFR \> best cut-off valve (0.5-0.55 assumed). With a power of 0.80 at an alpha level of 0.05, 118 RA grafts would be required to detect a statistically significant difference between groups. Assuming a 10% dropout rate and an average of 1.2 anastomosis per patient, sample size was defined at 110 patients. Therefore, the cohort size of ASRAB-pilot study of 150 patients is deemed adequate.
Analytic design and statistical analysis- Continuous variables were reported as mean, standard deviation, median, interquartile, minimum or maximum. For discrete categorical data, statistical description was presented as count and percentage. Missing data was treated as random missing. Unless otherwise stated, missing data was not filled in in this study.
Considering the possible heterogeneity between the sample population and the actual population for application, 2000 resampling samples were constructed through bootstrapping, and the mean value of QFR cut-off of all samples was taken as the final QFR cut-off. The determination of QFR cut-off value for a single sample adopted the minimum p-value method, taking RA, ITA or SV graft disease at 6 months after operation as endpoint index.
Considering the observational nature of this study, the cohort grouped based on the QFR cut-off may had imbalance of important factors. Therefore, the multivariate regression model and propensity scoring method were used to correct the potential confounding factors to evaluate the difference of outcome indicators between groups after the QFR cut-off grouping. The correlation between QFR and visual estimation was analyzed by the Spearman rank-order correlation coefficient. The predictive value of QFR and visual estimation for graft disease was compared by analyzing their respective ROC curve and corresponding AUC. Taking the QFR and the visual estimation as important prediction variables, a multifactor prediction model was constructed. The prediction accuracy was evaluated and compared by AUC. The prediction model was presented as nomograms, and the calibration curve and decision analysis curve were constructed.
The radial artery (RA) was first used by Carpentier for coronary artery bypass grafting (CABG) in 1971 because of a number of potential advantages, including ease of harvesting, a low propensity for wound infection, a larger diameter than other arterial grafts, and a thick, muscular wall that facilitates the construction of an anastomosis. However, early experience suggested that RA grafts were prone to spasm and functional occlusion, and their use was abandoned for many years. In the past decades, the advent of drug therapy to prevent graft spasm and the adoption of newer harvesting techniques revitalized the interest the use of radial artery. Recently several randomized trials has been conducted to prove the better graft patency over the saphenous vein (SV) and survival benefit was also observed as well. However, due to its unneglectable vulnerability to competitive flow, the recent American and European guidelines for coronary revascularization both limited the use of RA only in significantly stenosed vessels.
Fractional flow reserve (FFR) is the current gold standard to measure the physiological significance of coronary stenosis and the potential for competitive flow. The quantitative flow ratio (QFR) is a novel, intelligent, noninvasive method that enables efficient computation of the FFR from coronary angiography in good concordance with catheter-based FFR. QFR-guided percutaneous coronary intervention (PCI) has been used and showed the improved clinical outcomes in FAVOR III China trial (Comparison of Quantitative Flow Ratio-Guided and Angiography-Guided Percutaneous InterVention in Patients With cORonary Artery Disease).
The Impact of Preoperative Quantitative Flow Ratio on Radial-Artery Graft Outcome after Coronary Artery Bypass Grafting (ASRAB-QUARGO) study aims to investigate whether the preoperative QFR measurement is associated with RA graft patency 6 months after CABG, and to explore the best QFR cut-off value for guiding RA-CABG.
Methods:
Study design- The ASRAB-QUARGO is a single-centre, prospective, double-blind, observational sub-study of the ASRAB-pilot trial (NCT04310995). The study was registered and approved by the ethics committee in out institution. Informed consent was waived under permission from the ethics committee.
Outcome- The primary outcome is the association between preoperative QFR of target vessel and the RA graft outcome at 6 months after CABG. The secondary outcome is the association between preoperative QFR of target vessel and the RA graft outcome at 7 days after CABG.
Study procedures- The complete eligibility criteria for ASRAB-pilot trial is provided in the "eligibility" section. After successfully receiving primary isolated CABG, the patients from the ASRAB-pilot cohort with preoperative CAG images available for QFR analysis were enrolled in this study. QFR analysis was conducted in all vessels grafted based on preoperative CAG images. The images were sent to the core lab (CardHemo, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China) for computation of the QFR. The analysis was performed by the experienced analysts using the AngioPlus system (Pulse Medical Imaging Technology, Shanghai, China) as described \[11-15\]. QFR results were recorded by the core lab and blinded to the patient and surgeon. Apart from the investigational anti-spastic drug from the ASRAB-pilot trial, optimized medical treatment was pursued according to the current American and European guidelines, including smoking cessation counselling and the administration of antiplatelet agents, beta blockers, lipid medications, and angiotensin-converting enzyme inhibitors.
Patients underwent follow-up coronary computer tomography angiography （CCTA）6 months after surgery. Angiographic evaluations were performed by two observers (one radiologist and one cardiac surgeon) blinded to the preoperative QFR values. In the case of ambiguity or disagreement between observers, additional CAG is conducted as possible for further confirmation. For sequential grafts, each segment between two adjacent anastomoses (graft-to-graft anastomosis not included) will be defined as an independent graft and evaluated independently. For composite grafts (eg. T or Y grafts), only RAs directly anastomosed to target vessel were considered as RA grafts. Angiographic patency was graded referring to the FitzGibbon classification: 4 Grade A for widely patent, Grade B for patent with flow limited, Grade S for string sign and Grade O for occluded. Grade B, O and S were considered as diseased. MACE was defined as a composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke and unplanned coronary revascularization.
Sample size- Historical data from our center indicate that graft disease (Grade B, O \& S) occurs in around 20% of grafts 6 months after CABG. We estimated an RA graft disease rate of 10% if QFR ≤ best cut-off value (0.50-0.55 assumed), and 30% if QFR \> best cut-off valve (0.5-0.55 assumed). With a power of 0.80 at an alpha level of 0.05, 118 RA grafts would be required to detect a statistically significant difference between groups. Assuming a 10% dropout rate and an average of 1.2 anastomosis per patient, sample size was defined at 110 patients. Therefore, the cohort size of ASRAB-pilot study of 150 patients is deemed adequate.
Analytic design and statistical analysis- Continuous variables were reported as mean, standard deviation, median, interquartile, minimum or maximum. For discrete categorical data, statistical description was presented as count and percentage. Missing data was treated as random missing. Unless otherwise stated, missing data was not filled in in this study.
Considering the possible heterogeneity between the sample population and the actual population for application, 2000 resampling samples were constructed through bootstrapping, and the mean value of QFR cut-off of all samples was taken as the final QFR cut-off. The determination of QFR cut-off value for a single sample adopted the minimum p-value method, taking RA, ITA or SV graft disease at 6 months after operation as endpoint index.
Considering the observational nature of this study, the cohort grouped based on the QFR cut-off may had imbalance of important factors. Therefore, the multivariate regression model and propensity scoring method were used to correct the potential confounding factors to evaluate the difference of outcome indicators between groups after the QFR cut-off grouping. The correlation between QFR and visual estimation was analyzed by the Spearman rank-order correlation coefficient. The predictive value of QFR and visual estimation for graft disease was compared by analyzing their respective ROC curve and corresponding AUC. Taking the QFR and the visual estimation as important prediction variables, a multifactor prediction model was constructed. The prediction accuracy was evaluated and compared by AUC. The prediction model was presented as nomograms, and the calibration curve and decision analysis curve were constructed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Coronary Artery Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
QFR-Low Group
Based on preoperative CAG, QFR analysis will be conducted for vessels bypassed with RA grafts. The RA-grafted vessels with QFR below the best cut-off value (0.50-0.55 assumed) will be allocated to QFR-Low group.
No interventions assigned to this group
QFR-High Group
Based on preoperative CAG, QFR analysis will be conducted for vessels bypassed with RA grafts. The RA-grafted vessels with QFR over the best cut-off value (0.50-0.55 assumed) will be allocated to QFR-High group.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All patients enrolled in the ASRAB-pilot study.
* Age≥18 years.
* Male or female patients.
* Have signed informed consent.
* Have successfully accepted the first RA-CABG surgery.
* Age≥18 years.
* Male or female patients.
* Have signed informed consent.
* Have successfully accepted the first RA-CABG surgery.
Exclusion Criteria
* Preoperative CAG not available for QFR analysis.
* Previously experienced an allergy to active ingredients and/or excipients of experimental drugs.
* Hypotension (defined as systolic blood pressure \< 90mmHg or diastolic blood pressure \< 60mmHg) after surgery.
* Acute myocardial infarction, pulmonary congestion or cardiogenic shock after surgery.
* Concomitant medications with phosphodiesterase-5 inhibitors such as sildenafil, vardenafil, tadalafil, etc.
* Pathological sinus node syndrome, degree II or III atrioventricular block without cardiac pacemaker.
* Contraindications for coronary computed tomography angiography (CCTA) or coronary arteriography (CAG) examination, such as iodine allergy, etc. (note: patients with renal insufficiency or even end-stage renal disease whose hemodialysis can be tolerated by CCTA or CAG tests are eligible for inclusion).
* History or evidence of ongoing alcohol or drug abuse.
* Life expectancy \< 1 year judged by investigators.
* Other inappropriate situations judged by investigators.
* Previously experienced an allergy to active ingredients and/or excipients of experimental drugs.
* Hypotension (defined as systolic blood pressure \< 90mmHg or diastolic blood pressure \< 60mmHg) after surgery.
* Acute myocardial infarction, pulmonary congestion or cardiogenic shock after surgery.
* Concomitant medications with phosphodiesterase-5 inhibitors such as sildenafil, vardenafil, tadalafil, etc.
* Pathological sinus node syndrome, degree II or III atrioventricular block without cardiac pacemaker.
* Contraindications for coronary computed tomography angiography (CCTA) or coronary arteriography (CAG) examination, such as iodine allergy, etc. (note: patients with renal insufficiency or even end-stage renal disease whose hemodialysis can be tolerated by CCTA or CAG tests are eligible for inclusion).
* History or evidence of ongoing alcohol or drug abuse.
* Life expectancy \< 1 year judged by investigators.
* Other inappropriate situations judged by investigators.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qiang Zhao,MD
Professor and director, Department of Cardiac Surgery,Vice President of Ruijin Hospital
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qiang Zhao, MD
Role: PRINCIPAL_INVESTIGATOR
Ruijin Hospital
Yunpeng Zhu, MD
Role: STUDY_DIRECTOR
Ruijin Hospital
Jiaxi Zhu, MD
Role: STUDY_DIRECTOR
Ruijin Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
References
Explore related publications, articles, or registry entries linked to this study.
Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, Disesa VJ, Hiratzka LF, Hutter AM Jr, Jessen ME, Keeley EC, Lahey SJ, Lange RA, London MJ, Mack MJ, Patel MR, Puskas JD, Sabik JF, Selnes O, Shahian DM, Trost JC, Winniford MD. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011 Dec 6;124(23):e652-735. doi: 10.1161/CIR.0b013e31823c074e. Epub 2011 Nov 7. No abstract available.
Reference Type
BACKGROUND
Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/eurheartj/ehy394. No abstract available.
Reference Type
BACKGROUND
Lytle BW, Blackstone EH, Loop FD, Houghtaling PL, Arnold JH, Akhrass R, McCarthy PM, Cosgrove DM. Two internal thoracic artery grafts are better than one. J Thorac Cardiovasc Surg. 1999 May;117(5):855-72. doi: 10.1016/S0022-5223(99)70365-X.
Reference Type
BACKGROUND
Taggart DP, D'Amico R, Altman DG. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet. 2001 Sep 15;358(9285):870-5. doi: 10.1016/S0140-6736(01)06069-X.
Reference Type
BACKGROUND
Yi G, Shine B, Rehman SM, Altman DG, Taggart DP. Effect of bilateral internal mammary artery grafts on long-term survival: a meta-analysis approach. Circulation. 2014 Aug 12;130(7):539-45. doi: 10.1161/CIRCULATIONAHA.113.004255. Epub 2014 Jun 10.
Reference Type
BACKGROUND
Aldea GS, Bakaeen FG, Pal J, Fremes S, Head SJ, Sabik J, Rosengart T, Kappetein AP, Thourani VH, Firestone S, Mitchell JD; Society of Thoracic Surgeons. The Society of Thoracic Surgeons Clinical Practice Guidelines on Arterial Conduits for Coronary Artery Bypass Grafting. Ann Thorac Surg. 2016 Feb;101(2):801-9. doi: 10.1016/j.athoracsur.2015.09.100. Epub 2015 Dec 8.
Reference Type
BACKGROUND
Glineur D, Poncelet A, El Khoury G, D'hoore W, Astarci P, Zech F, Noirhomme P, Hanet C. Fractional flow reserve of pedicled internal thoracic artery and saphenous vein grafts 6 months after bypass surgery. Eur J Cardiothorac Surg. 2007 Mar;31(3):376-81. doi: 10.1016/j.ejcts.2006.11.023. Epub 2006 Dec 14.
Reference Type
BACKGROUND
Glineur D, Hanet C. Competitive flow in coronary bypass surgery: is it a problem? Curr Opin Cardiol. 2012 Nov;27(6):620-8. doi: 10.1097/HCO.0b013e3283583000.
Reference Type
BACKGROUND
Glineur D, D'hoore W, El Khoury G, Sondji S, Kalscheuer G, Funken JC, Rubay J, Poncelet A, Astarci P, Verhelst R, Noirhomme P, Hanet C. Angiographic predictors of 6-month patency of bypass grafts implanted to the right coronary artery a prospective randomized comparison of gastroepiploic artery and saphenous vein grafts. J Am Coll Cardiol. 2008 Jan 15;51(2):120-5. doi: 10.1016/j.jacc.2007.09.030.
Reference Type
BACKGROUND
Glineur D, Hanet C, D'hoore W, Poncelet A, De Kerchove L, Etienne PY, Noirhomme P, El Khoury G. Causes of non-functioning right internal mammary used in a Y-graft configuration: insight from a 6-month systematic angiographic trial. Eur J Cardiothorac Surg. 2009 Jul;36(1):129-35; discussion 135-6. doi: 10.1016/j.ejcts.2009.02.041. Epub 2009 Apr 15.
Reference Type
BACKGROUND
Sabik JF 3rd, Lytle BW, Blackstone EH, Khan M, Houghtaling PL, Cosgrove DM. Does competitive flow reduce internal thoracic artery graft patency? Ann Thorac Surg. 2003 Nov;76(5):1490-6; discussion 1497. doi: 10.1016/s0003-4975(03)01022-1.
Reference Type
BACKGROUND
White CW, Wright CB, Doty DB, Hiratza LF, Eastham CL, Harrison DG, Marcus ML. Does visual interpretation of the coronary arteriogram predict the physiologic importance of a coronary stenosis? N Engl J Med. 1984 Mar 29;310(13):819-24. doi: 10.1056/NEJM198403293101304.
Reference Type
BACKGROUND
Xu B, Tu S, Qiao S, Qu X, Chen Y, Yang J, Guo L, Sun Z, Li Z, Tian F, Fang W, Chen J, Li W, Guan C, Holm NR, Wijns W, Hu S. Diagnostic Accuracy of Angiography-Based Quantitative Flow Ratio Measurements for Online Assessment of Coronary Stenosis. J Am Coll Cardiol. 2017 Dec 26;70(25):3077-3087. doi: 10.1016/j.jacc.2017.10.035. Epub 2017 Oct 31.
Reference Type
BACKGROUND
Westra J, Andersen BK, Campo G, Matsuo H, Koltowski L, Eftekhari A, Liu T, Di Serafino L, Di Girolamo D, Escaned J, Nef H, Naber C, Barbierato M, Tu S, Neghabat O, Madsen M, Tebaldi M, Tanigaki T, Kochman J, Somi S, Esposito G, Mercone G, Mejia-Renteria H, Ronco F, Botker HE, Wijns W, Christiansen EH, Holm NR. Diagnostic Performance of In-Procedure Angiography-Derived Quantitative Flow Reserve Compared to Pressure-Derived Fractional Flow Reserve: The FAVOR II Europe-Japan Study. J Am Heart Assoc. 2018 Jul 6;7(14):e009603. doi: 10.1161/JAHA.118.009603.
Reference Type
BACKGROUND
Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M, Murasato Y, Lansky A, Barbato E, van der Heijden LC, Reiber JHC, Holm NR, Wijns W; FAVOR Pilot Trial Study Group. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study. JACC Cardiovasc Interv. 2016 Oct 10;9(19):2024-2035. doi: 10.1016/j.jcin.2016.07.013.
Reference Type
BACKGROUND
Tu S, Westra J, Adjedj J, Ding D, Liang F, Xu B, Holm NR, Reiber JHC, Wijns W. Fractional flow reserve in clinical practice: from wire-based invasive measurement to image-based computation. Eur Heart J. 2020 Sep 7;41(34):3271-3279. doi: 10.1093/eurheartj/ehz918.
Reference Type
BACKGROUND
Xu B, Tu S, Song L, Jin Z, Yu B, Fu G, Zhou Y, Wang J, Chen Y, Pu J, Chen L, Qu X, Yang J, Liu X, Guo L, Shen C, Zhang Y, Zhang Q, Pan H, Fu X, Liu J, Zhao Y, Escaned J, Wang Y, Fearon WF, Dou K, Kirtane AJ, Wu Y, Serruys PW, Yang W, Wijns W, Guan C, Leon MB, Qiao S, Stone GW; FAVOR III China study group. Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. Lancet. 2021 Dec 11;398(10317):2149-2159. doi: 10.1016/S0140-6736(21)02248-0. Epub 2021 Nov 4.
Reference Type
BACKGROUND
Glineur D, Grau JB, Etienne PY, Benedetto U, Fortier JH, Papadatos S, Laruelle C, Pieters D, El Khoury E, Blouard P, Timmermans P, Ruel M, Chong AY, So D, Chan V, Rubens F, Gaudino MF. Impact of preoperative fractional flow reserve on arterial bypass graft anastomotic function: the IMPAG trial. Eur Heart J. 2019 Aug 1;40(29):2421-2428. doi: 10.1093/eurheartj/ehz329.
Reference Type
BACKGROUND
Glineur D, Rahouma M, Grau JB, Etienne PY, Fortier JH, Papadatos S, Laruelle C, Pieters D, El Khoury E, Gaudino M. FFR Cutoff by Arterial Graft Configuration and Location: IMPAG Trial Insights. JACC Cardiovasc Interv. 2020 Jan 13;13(1):143-144. doi: 10.1016/j.jcin.2019.08.013. No abstract available.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY-2022144
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Randomized Study for the Optimal Treatment of Symptomatic Patients With Low Gradient Severe Aortic Valve Stenosis and Preserved Left Ventricular Ejection Fraction
NCT03667365
TERMINATED
NA
Strategies for Revascularization in Patients Undergoing Heart Valve Surgery With Concomitant Coronary Artery Disease
NCT02173860
UNKNOWN
NA
Complete Functional Assessment of Intermediate Coronary Artery Stenosis Before and After Transcatheter Aortic Valve Implantation (TAVI) in Patients With Severe Symptomatic Aortic Valve Stenosis
NCT05133843
RECRUITING
NA
Coronary Artery Bypass Grafting With Ascending Aortic Replacement
NCT07071857
COMPLETED
NA
Videodensitometric Angiographic Assessment of AR in the Cath-lab for Intraprocedural Guidance of TAVI in CHINA
NCT06891079
ENROLLING_BY_INVITATION
NA
Multimodal Imaging Evaluation and Prognostic Analysis of Participants After Arterial Switch Operation
NCT04980339
NOT_YET_RECRUITING
Pressure Gradient vs. Flow Relationships in Patients With Symptomatic Valvular Aortic Stenosis
NCT05580237
COMPLETED
Antegrade Cerebral Perfusion and Retrograde Inferior Vena Caval Perfusion for Total Aortic Arch Replacement
NCT03607786
UNKNOWN
NA
Accuracy of LAA Occluder Size Selection: CT vs. DSA During Combined AF Ablation and LAA Occlusion
NCT06455644
RECRUITING
NA
Change in Coronary Microcirculation and FFR After TAVI in Patients With Cardiovascular Comorbidities
NCT04663334
COMPLETED
Novel Echocardiographic and Invasive Haemodynamic Measurements in the Assessment of Patients Low Flow Low Gradient Aortic Stenosis Undergoing TAVI
NCT05196815
COMPLETED
NA
Comprehensive CT-guided vs Echo-fluoroscopy-guided Strategy in the Left Atrial Appendage Occlusion
NCT04913207
UNKNOWN
NA
Blood Transfusion Management in Patients With Mitral Valve Replacement in China
NCT03885570
UNKNOWN
A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis
NCT07335900
RECRUITING
NA
Complete Revascularization Via Inferior Part-sternotomy
NCT05835167
NOT_YET_RECRUITING
NA
TAVR in Adults With Pure Severe Aortic Regurgitation
NCT05737264
UNKNOWN
Safety and Efficacy of Emergent TAVI in Patients With Severe AS
NCT05528211
NOT_YET_RECRUITING
Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis
NCT06589063
RECRUITING
Clinical Outcome of Patients With Low-gradient Severe Aortic Stenosis
NCT02010177
SUSPENDED
Outcomes for Patients With Ascending Aortic Dilation Who Underwent TAVR
NCT07148973
COMPLETED
Anatomical Assessment Versus Pull Back RFR Measurement
NCT04857762
UNKNOWN
Preoperative Chest CT-imaging in Surgical Aortic Valve Replacement with or Without CABG
NCT06603454
RECRUITING
NA
Transcatheter Implantation of Aortic Bioprosthesis Without the Use of Iodinated Contrast in Patients With Chronic Kidney Disease
NCT04581694
UNKNOWN
NA
accuRate Evaluation of Benefit With Optimal Medical Treatment With or Without Transcatheter Valve Repair of PARADOXical Low Flow Low Gradient Aortic Stenosis
NCT03863132
ACTIVE_NOT_RECRUITING
NA
Evaluation of ARi With OpSens SavvyWire
NCT06295068
TERMINATED